Lisa Delfini
CIK: 0001873253
Transaction Breakdown
High conviction signal
Position reduction
Derivative conversions
Compensation grants
Gifts, tax withholding, conversions, dispositions to the issuer and other codes
Companies & Roles (1)
Trevi Therapeutics, Inc.
Discretionary Trading P&L
Holdings
Transaction History (5 total)
- May 31, 2025TRVI
Trevi Therapeutics, Inc.
Award(A)DirectPerformance Stock Option (right to buy)
72K shares- - Mar 10, 2025TRVI
Trevi Therapeutics, Inc.
Award(A)DirectPerformance Stock Option (right to buy)
38.4K shares- - Feb 18, 2025TRVI
Trevi Therapeutics, Inc.
Award(A)DirectStock Option (right to buy)
225.5K shares- - Jan 8, 2025TRVI
Trevi Therapeutics, Inc.
Exercise(M)Direct5K shares at avg. $0.51$3K - Jan 7, 2025TRVI
Trevi Therapeutics, Inc.
Exercise(M)Direct1K shares at avg. $0.51$511
| Type | Shares | Price | Ownership | |||
|---|---|---|---|---|---|---|
| May 31, 2025 | TRVI Trevi Therapeutics, Inc. | Award(A) Performance Stock Option (right to buy) | 72,000 | - | - | Direct |
| Mar 10, 2025 | TRVI Trevi Therapeutics, Inc. | Award(A) Performance Stock Option (right to buy) | 38,400 | - | - | Direct |
| Feb 18, 2025 | TRVI Trevi Therapeutics, Inc. | Award(A) Stock Option (right to buy) | 225,500 | - | - | Direct |
| Jan 8, 2025 | TRVI Trevi Therapeutics, Inc. | Exercise(M) | 5,000 | $0.51 | $2,555 | Direct |
| Jan 7, 2025 | TRVI Trevi Therapeutics, Inc. | Exercise(M) | 1,000 | $0.51 | $511 | Direct |
1-5 of 5 transactions
About Delfini Lisa
Delfini Lisa (SEC CIK 0001873253) files insider reports with the SEC as Chief Financial Officer of Trevi Therapeutics, Inc. (TRVI).
Signal8 holds 4 ownership filings by Delfini Lisa, all Form 4s, filed between Jan 10, 2025 and Jun 3, 2025. Those filings report 5 transactions, from Jan 7, 2025 to May 31, 2025. Signal8's Form 4 history starts in Sep 2024.
The business address on Delfini Lisa's filings is in NEW HAVEN, CT.
Recent filings by Delfini Lisa
- May 31, 2025: Grant or award of TRVI derivative securities (Form 4, code A).
- Mar 10, 2025: Grant or award of TRVI derivative securities (Form 4, code A).
- Feb 18, 2025: Grant or award of TRVI derivative securities (Form 4, code A).
- Jan 8, 2025: Option exercise of TRVI shares (Form 4, code M).
- Jan 7, 2025: Option exercise of TRVI shares (Form 4, code M).
Other insiders filing for Trevi Therapeutics, Inc. (TRVI)
- Heffernan Michael Thomas, Director
- Mathers Edward T, Director
- Colangelo Dominick, Director
- Meeker David P, Director
- VANLENT ANNE, Director
- Cassella James V, Chief Development Officer